{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T06:03:50Z","timestamp":1788329030931,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"15. Sumitomo Pharma Switzerland GmbH"},{"name":"Pfizer, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s11523-025-01139-3","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T13:47:59Z","timestamp":1743860879000},"page":"503-517","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6036-5753","authenticated-orcid":false,"given":"Jose","family":"De La Cerda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Belkoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Courtney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elan","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"D\u2019Olimpio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Dunshee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Gervasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kriti","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Tutrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Ufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"1139_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1139_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1139_CR3","unstructured":"Schaeffer EM, Srinivas S, Adra N, Ahmed B, An Y, Bitting R, et al. NCCN clinical practice guidelines in oncology. Prostate cancer. Version 1.2025. Prostate Cancer. 2024;Version 1.2025."},{"key":"1139_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2024;86:164\u201382.","journal-title":"Eur Urol"},{"key":"1139_CR5","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2017.7248","volume":"317","author":"MS Litwin","year":"2017","unstructured":"Litwin MS, Tan H-J. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317:2532\u201342.","journal-title":"JAMA"},{"key":"1139_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86:148\u201363.","journal-title":"Eur Urol"},{"key":"1139_CR7","first-page":"87","volume":"14","author":"E Choi","year":"2022","unstructured":"Choi E, Buie J, Camacho J, Sharma P, de Riese WTW. Evolution of androgen deprivation therapy (ADT) and its new emerging modalities in prostate cancer: an update for practicing urologists, clinicians and medical providers. Res Rep Urol. 2022;14:87\u2013108.","journal-title":"Res Rep Urol."},{"key":"1139_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","volume":"22","author":"ED Crawford","year":"2019","unstructured":"Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2019;22:24\u201338.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1139_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/pcan.2012.25","volume":"16","author":"ND Shore","year":"2013","unstructured":"Shore ND, Abrahamsson P-A, Anderson J, Crawford ED, Lange P. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer Prostatic Dis. 2013;16:7\u201315.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1139_CR10","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/j.1442-2042.2012.02997.x","volume":"19","author":"H Van Poppel","year":"2012","unstructured":"Van Poppel H, Klotz L. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. Int J Urol. 2012;19:594\u2013601.","journal-title":"Int J Urol"},{"key":"1139_CR11","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1093\/oncolo\/oyad099","volume":"28","author":"LM Cordes","year":"2023","unstructured":"Cordes LM, Karzai F, Figg WD, Madan RA. Relugolix in clinical practice: the best route for all? Oncologist. 2023;28:647\u201350.","journal-title":"Oncologist"},{"key":"1139_CR12","doi-asserted-by":"publisher","first-page":"175883592199858","DOI":"10.1177\/1758835921998586","volume":"13","author":"F Saad","year":"2021","unstructured":"Saad F, Shore ND. Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer. Ther Adv Med Oncol. 2021;13:1758835921998586.","journal-title":"Ther Adv Med Oncol."},{"key":"1139_CR13","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/14737140.2022.2105209","volume":"22","author":"KK Sahu","year":"2022","unstructured":"Sahu KK, Tripathi N, Agarwal N, Swami U. Relugolix in the management of prostate cancer. Expert Rev Anticancer Ther. 2022;22:891\u2013902.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1139_CR14","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","volume":"102","author":"L Klotz","year":"2008","unstructured":"Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson B-E, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102:1531\u20138.","journal-title":"BJU Int"},{"key":"1139_CR15","first-page":"CD012548","volume":"8","author":"F Zengerling","year":"2021","unstructured":"Zengerling F, Jakob JJ, Schmidt S, Meerpohl JJ, Bl\u00fcmle A, Schmucker C, et al. Degarelix for treating advanced hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2021;8:CD012548.","journal-title":"Cochrane Database Syst Rev"},{"key":"1139_CR16","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.6004\/jnccn.2015.0109","volume":"13","author":"VK Pokuri","year":"2015","unstructured":"Pokuri VK, Nourkeyhani H, Betsy B, Herbst L, Sikorski M, Spangenthal E, et al. Strategies to circumvent testosterone surge and disease flare in advanced prostate cancer: emerging treatment paradigms. J Natl Compr Cancer Netw JNCCN. 2015;13:e49-55.","journal-title":"J Natl Compr Cancer Netw JNCCN."},{"key":"1139_CR17","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/iju.14303","volume":"27","author":"H Van Poppel","year":"2020","unstructured":"Van Poppel H, Abrahamsson P-A. Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer. Int J Urol. 2020;27:830\u20137.","journal-title":"Int J Urol"},{"key":"1139_CR18","first-page":"73","volume":"4","author":"JC Arjona Ferreira","year":"2023","unstructured":"Arjona Ferreira JC, Migoya E. Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis. FS Rep. 2023;4:73\u201382.","journal-title":"FS Rep."},{"key":"1139_CR19","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","volume":"382","author":"ND Shore","year":"2020","unstructured":"Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382:2187\u201396.","journal-title":"N Engl J Med"},{"key":"1139_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11523-022-00944-4","volume":"18","author":"M Shirley","year":"2023","unstructured":"Shirley M. Relugolix: a review in advanced prostate cancer. Target Oncol. 2023;18:295\u2013302.","journal-title":"Target Oncol"},{"key":"1139_CR21","unstructured":"US Food and Drug Administration\u2014Center for Drug Evaluation and Research. Relugolix: multi-discipline review. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/214621Orig1s000MultidisciplineR.pdf. Accessed 28 Mar 2025."},{"key":"1139_CR22","unstructured":"ORGOVYX Prescribing Information [Internet]. 2024. https:\/\/www.orgovyx.com\/content\/pdfs\/orgovyx-prescribing-information.pdf. Accessed 28 Mar 2025."},{"key":"1139_CR23","unstructured":"ORGOVYX (relugolix)\u2014summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/orgovyx-epar-product-information_en.pdf. Accessed 28 Mar 2025."},{"key":"1139_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.clgc.2020.08.008","volume":"19","author":"ND Shore","year":"2021","unstructured":"Shore ND, Morgans AK, Ryan CJ. Resetting the bar of castration resistance\u2014understanding androgen dynamics in therapy resistance and treatment choice in prostate cancer. Clin Genitourin Cancer. 2021;19:199\u2013207.","journal-title":"Clin Genitourin Cancer"},{"key":"1139_CR25","unstructured":"NCCN clinical practice guidelines in oncology. Prostate cancer. Version 1.2025. 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed 28 Mar 2025."},{"key":"1139_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:13\u201324.","journal-title":"N Engl J Med"},{"key":"1139_CR27","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352\u201360.","journal-title":"N Engl J Med"},{"key":"1139_CR28","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO-24-01798","volume":"42","author":"F Saad","year":"2024","unstructured":"Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira De Santana Gomes AJ, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE Trial. J Clin Oncol. 2024;42:4271-81.","journal-title":"J Clin Oncol"},{"key":"1139_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121\u201331.","journal-title":"N Engl J Med"},{"key":"1139_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102096","volume":"22","author":"F Paolieri","year":"2024","unstructured":"Paolieri F, Sammarco E, Ferrari M, Salfi A, Bonato A, Serafin D, et al. Front-line therapeutic strategy in metastatic hormone sensitive prostate cancer: an updated therapeutic algorithm. Clin Genitourin Cancer. 2024;22: 102096.","journal-title":"Clin Genitourin Cancer"},{"key":"1139_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1586\/era.11.196","volume":"12","author":"DJ Bedoya","year":"2012","unstructured":"Bedoya DJ, Mitsiades N. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2012;12:1\u20133.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1139_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/DDDT.S15850","volume":"6","author":"Y Rehman","year":"2012","unstructured":"Rehman Y, Rosenberg JE. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des Devel Ther. 2012;6:13\u20138.","journal-title":"Drug Des Devel Ther."},{"key":"1139_CR33","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338\u201351.","journal-title":"N Engl J Med"},{"key":"1139_CR34","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360.","journal-title":"Lancet Oncol"},{"key":"1139_CR35","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1634\/theoncologist.2014-0167","volume":"19","author":"RJ Auchus","year":"2014","unstructured":"Auchus RJ, Yu MK, Nguyen S, Mundle SD. Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. Oncologist. 2014;19:1231\u201340.","journal-title":"Oncologist"},{"issue":"Suppl","key":"1139_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1200\/JCO.2024.42.4_suppl.67","volume":"42","author":"M Goryachok","year":"2024","unstructured":"Goryachok M, Nicklawsky A, Ahmad H, Flaig T. Effect of prednisone dosing on mineralocorticoid-related side effects with abiraterone in prostate cancer. J Clin Oncol. 2024;42(Suppl):67.","journal-title":"J Clin Oncol"},{"key":"1139_CR37","first-page":"501","volume":"10","author":"UJ Patel","year":"2019","unstructured":"Patel UJ, Caulfield S. Apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer. J Adv Pract Oncol. 2019;10:501\u20137.","journal-title":"J Adv Pract Oncol"},{"key":"1139_CR38","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39:2294\u2013303.","journal-title":"J Clin Oncol"},{"key":"1139_CR39","unstructured":"ERLEADA\u00ae (apalutamide) tablets. 2024. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/ERLEADA-pi.pdf. Accessed 28 Mar 2025."},{"key":"1139_CR40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11523-023-00967-5","volume":"18","author":"J De La Cerda","year":"2023","unstructured":"De La Cerda J, Dunshee C, Gervasi L, Sieber P, Belkoff L, Tutrone R, et al. A phase I clinical trial evaluating the safety and dosing of Relugolix with novel hormonal therapy for the treatment of advanced prostate cancer. Target Oncol. 2023;18:383\u201390.","journal-title":"Target Oncol"},{"issue":"Supplement_1","key":"1139_CR41","doi-asserted-by":"publisher","first-page":"hvad097.037","DOI":"10.1093\/clinchem\/hvad097.037","volume":"69","author":"SL Daly","year":"2023","unstructured":"Daly SL, Kochuparambi J, Wu Z, Abdula R, Yuan C, et al. An improved multiplexed HTLC-HESI-MSMS method for the measurement of total testosterone in serum. Clin Chem. 2023;69(Supplement_1):hvad097.037.","journal-title":"Clin Chem"},{"key":"1139_CR42","unstructured":"Lee S, Chen Y-S, Chen Y-L. A Sensitive LC\u2013MS\/MS method for Relugolix quantification in human plasma and its application to a clinical Study. ASMS 2024. https:\/\/www.abstracts.asms.org\/pages\/dashboard.html#\/conference\/302\/toc\/302\/details. Accessed 28 Mar 2025."},{"key":"1139_CR43","unstructured":"US Food and Drug Administration\u2013Center for Drug Evaluation Research. Myfembree\u00ae: Clinical Pharmacology and Biopharmaceutics review(s). 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/214846Orig1s000ClinPharmR.pdf. Accessed 28 Mar 2025."},{"key":"1139_CR44","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1056\/NEJMoa031918","volume":"350","author":"IM Thompson","year":"2004","unstructured":"Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350:2239\u201346.","journal-title":"N Engl J Med"},{"key":"1139_CR45","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00280-018-3632-6","volume":"82","author":"BPSI Belderbos","year":"2018","unstructured":"Belderbos BPSI, de Wit R, Chien C, Mitselos A, Hellemans P, Jiao J, et al. An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2018;82:457\u201368.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1139_CR46","unstructured":"US Food and Drug Administration\u2013Center for Drug Evaluation and Research. Apalutamide: multi-discipline review. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/214621Orig1s000MultidisciplineR.pdf. Accessed 28 Mar 2025."},{"key":"1139_CR47","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J Urol. 2023;209:1082\u201390.","journal-title":"J Urol"},{"key":"1139_CR48","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen Y-H, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36:1080\u20137.","journal-title":"J Clin Oncol"},{"key":"1139_CR49","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","volume":"70","author":"G Gravis","year":"2016","unstructured":"Gravis G, Boher J-M, Joly F, Souli\u00e9 M, Albiges L, Priou F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70:256\u201362.","journal-title":"Eur Urol"},{"key":"1139_CR50","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974\u201386.","journal-title":"J Clin Oncol"},{"key":"1139_CR51","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","volume":"76","author":"AP Hoyle","year":"2019","unstructured":"Hoyle AP, Ali A, James ND, Cook A, Parker CC, De Bono JS, et al. Abiraterone in \u201chigh-\u201d and \u201clow-risk\u201d metastatic hormone-sensitive prostate cancer. Eur Urol. 2019;76:719\u201328.","journal-title":"Eur Urol"},{"key":"1139_CR52","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.clgc.2023.03.009","volume":"21","author":"DJ George","year":"2023","unstructured":"George DJ, Saad F, Cookson MS, Saltzstein DR, Tutrone R, Bossi A, et al. Impact of concomitant prostate cancer medications on efficacy and safety of Relugolix versus leuprolide in men with advanced prostate cancer. Clin Genitourin Cancer. 2023;21:383-392.e2.","journal-title":"Clin Genitourin Cancer"},{"key":"1139_CR53","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/10600280231223213","volume":"58","author":"B Lam","year":"2024","unstructured":"Lam B, Rodgers JE, Muluneh B, Proco D, Whang YE, Morgan KP. Real-world incidence and severity of hypertension caused by abiraterone acetate in patients with metastatic prostate cancer. Ann Pharmacother. 2024;58:994\u20131002.","journal-title":"Ann Pharmacother"},{"key":"1139_CR54","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1210\/jc.2011-2189","volume":"97","author":"G Attard","year":"2012","unstructured":"Attard G, Reid AHM, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab. 2012;97:507\u201316.","journal-title":"J Clin Endocrinol Metab"},{"key":"1139_CR55","unstructured":"ZYTIGA\u00ae (abiraterone acetate) Prescribing Information. 2024. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/ZYTIGA-pi.pdf. Accessed 28 Mar 2025."},{"key":"1139_CR56","unstructured":"YONSA\u00ae (abiraterone acetate) tablets. 2022. https:\/\/www.yonsarx.com\/pdfs\/Yonsa-PI-July-2022.pdf. Accessed 28 Mar 2025."},{"key":"1139_CR57","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2021.39.6_suppl.106","volume":"39","author":"DJ George","year":"2021","unstructured":"George DJ. Impact of concomitant prostate cancer therapy on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer: subgroup analysis from the phase III HERO study. J Clin Oncol. 2021;39:106\u2013106.","journal-title":"J Clin Oncol"},{"key":"1139_CR58","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402\u201318.","journal-title":"J Clin Oncol"},{"key":"1139_CR59","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/UPJ.0000000000000445","volume":"10","author":"J Hafron","year":"2023","unstructured":"Hafron J, Sangha P, Kung T, Pruett J. Adherence to hormonal therapies in prostate cancer. Urol Pract. 2023;10:540\u20136.","journal-title":"Urol Pract"},{"issue":"6_Suppl","key":"1139_CR60","doi-asserted-by":"publisher","first-page":"TPS398","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS398","volume":"41","author":"DE Spratt","year":"2023","unstructured":"Spratt DE, McKay RR, Dorff T, Lowentritt B, Fallick M, Hanson S, et al. A multi-center, prospective, observational study of prostate cancer patients being treated with relugolix: OPTYX. J Clin Oncol. 2023;41(6_Suppl):TPS398.","journal-title":"J Clin Oncol"},{"key":"1139_CR61","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11523-022-00932-8","volume":"18","author":"G Brown","year":"2023","unstructured":"Brown G, Belkoff L, Hafron JM, Saltzstein DR, Potdar R, Bhaumik A, et al. Coadministration of apalutamide and relugolix in patients with localized prostate cancer at high risk for metastases. Target Oncol. 2023;18:95\u2013103.","journal-title":"Target Oncol"},{"key":"1139_CR62","doi-asserted-by":"publisher","first-page":"e17094","DOI":"10.1200\/JCO.2023.41.16_suppl.e17094","volume":"41","author":"G Brown","year":"2023","unstructured":"Brown G, Belkoff L, Hafron J, Aggarwal P, Potdar R, Bhaumik A, et al. Maintenance of castration with concomitant relugolix and apalutamide (Apa) in patients with high-risk localized prostate cancer (HR-LPC): 1 year update. J Clin Oncol. 2023;41:e17094\u2013e17094.","journal-title":"J Clin Oncol"},{"key":"1139_CR63","doi-asserted-by":"crossref","unstructured":"Lee T-Y, Pierrillas PB, Lin Y-W, de Greef R. Population PK and semi\u2010mechanistic PK\/PD modeling and simulation of relugolix effects on testosterone suppression in men with prostate cancer. Clin Pharmacol Ther. 2023;113:124-34.","DOI":"10.1002\/cpt.2743"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01139-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01139-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01139-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T13:02:34Z","timestamp":1748264554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01139-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1139"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01139-3","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"17 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Sumitomo Pharma Switzerland GmbH in collaboration with Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jose De La Cerda has received honoraria from Johnson & Johnson, Pfizer, Dendreon, Foundation Medicine, and AstraZeneca; has been a consultant\/advisor for Johnson & Johnson, Pfizer, Dendreon, Foundation Medicine, and AstraZeneca; has received research funding from Urology San Antonio; and has been part of the speakers' bureau for Johnson & Johnson and Foundation Medicine. Laurence Belkoff has been a consultant\/advisor for Johnson & Johnson, Merck, Johnson & Johnson, Fellow Health, Exo Dx, Lantheus Medical Imaging, Blue Earth, Francis Medical, Boston Scientific, AstraZeneca, Propella Therapeutics, Dendreon, CG Oncology, and Immunity Bio, Ferring, and Prodeon Medical. Kevin D. Courtney has been a consultant\/advisor for Novartis and has received research funding from Sumitomo Pharma\/Myovant Sciences, Astellas Pharma, Lilly, Stemline Therapeutics, Clovis Oncology, Exelixis, Amgen, Harpoon Therapeutics, Pfizer, Surface Oncology, Novartis, Celgene\/Bristol-Myers Squibb, AstraZeneca, Janssen Research and Development, and DualityBio. Elan Diamond received honoraria from Bayer and has been a consultant\/advisor for AstraZeneca, Merck, and Bristol-Myers Squibb\/Sanofi. Curtis Dunshee has been a consultant\/advisor for Astellas, Bayer, Janssen, and Pfizer and has received research funding from Astellas, AstraZeneca, Bayer, Dendreon, Essa Pharmaceuticals, Pfizer, and Sumitomo Pharma. Michael Goodman received honoraria from Curio Science and Targeted Oncology and has been a consultant\/advisor for Sanofi\/Aventis and Alexion Pharmaceuticals. He has received research funding from Janssen, AstraZeneca, Genentech, and Bristol-Myers Squibb\/Pfizer; and has received travel, accommodations, and expenses from AstraZeneca, Genentech, and Curio Science. Kriti Mittal has received honoraria from IntrinsiQ, Targeted Oncology, Medpage, Aptitude Health, and Cardinal Health. She has been a consultant\/advisor for Bayer, Aveo, Dendreon, Myovant Sciences, Curio Science, and Janssen AstraZeneca and has received research funding from Pfizer. David Morris has been a consultant\/advisor for Janssen Oncology, Clovis Oncology, Astellas Pharma, Bayer, Urogen Pharma, Myriad Genetics, UROGPO, Pfizer\/EMD Serono, Decipher Biosciences, AstraZeneca, Myovant Sciences, Merck Serono, Dendreon, Blue Earth Diagnostics, and Lantheus Medical Imaging. He has received research funding from Merck, Janssen Oncology, Astellas Pharma, Urogen Pharma, Pfizer\/Astellas, Dendreon, Exelixis, Bayer, Clovis Oncology, and AstraZeneca\/Merck; and has also been part of the speakers' bureau for AstraZeneca, Janssen, Clovis Oncology, Astellas Medivation, and Merck. Paul Sieber received honoraria from Bayer, Pfizer, and Foundation Medicine and has received research funding from Astellas Pharma, Pfizer, AstraZeneca, Merck, ORIC Pharmaceuticals, CG Therapeutics, Janssen, Dendreon, and Bayer. He has been part of the speakers' bureau for Astellas Pharma, Bayer, Dendreon, Merck, Pfizer, Janssen, Bayer Germany, Pfizer\/NCCN, Dendreon, Astellas, and Merck. Ronald Tutrone has been a consultant\/advisor for Astellas and has received research funding from Astellas, Arvinas, AstraZeneca, Bayer, Dendreon, Essa Pharmaceuticals, Merck, OncC4, Pfizer, Janssen, and Sumitomo Pharma. Michael Ryan is an employee of Pfizer, Inc. Yi Zhong is an employee of Sumitomo Pharma America, Inc. Mike Ufer is an employee of Sumitomo Pharma Switzerland GmbH. Neal Shore has been a consultant\/advisor for Bayer, Janssen Scientific Affairs, Dendreon, Tolmar, Ferring, Medivation\/Astellas, Amgen, Pfizer, AstraZeneca, Astellas Pharma, Merck, Bristol-Myers Squibb\/Sanofi, Exact Imaging, InVitae, MDxHealth, Myriad Genetics, Propella Therapeutics, Sanofi, Urogen Pharma, Specialty Networks, Peerview, Clarity Pharmaceuticals, Lantheus Medical Imaging, Lilly, Photocure, Telix Pharmaceuticals, Arquer Diagnostics, Asieris Pharmaceuticals, Minomic, Novartis, PlatformQ Health, Promaxo, Protara Therapeutics, Fize Medical, Accord Research, Antev, Aura Biosciences, Bioprotect, Sumitomo Pharma, Siemens, Alessa Therapeutics, CG Oncology, Glytherix, and Tutelix. He has received research funding from Abbvie, Amgen, Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb\/Pfizer, Boston Scientific, Clovis Oncology, Dendreon, Exact Imaging, Ferring, Foundation Medicine, InVitae, Janssen, MDxHealth, Merck, Myovant Sciences, Myriad Genetics, Nymox, Pfizer, Sanofi, Sesen Bio, Tolmar, CG Oncology, DisperSol, FORMA Therapeutics, Guardant Health, Jiangsu Yahong Meditech, Novartis, Pacific Edge, POINT Biopharma, Propella Therapeutics, SeaGen, MT Group, Theralase, Veru, Zenflow, Advantagene, Aragon Pharmaceuticals, Endocyte, Exelixis, FKD Therapies, Genentech, ISTARI Oncology, Medivation, OncoCellMDx, ORIC Pharmaceuticals, Palette Life Sciences, Plexxikon, RhoVac, Steba Biotech, Urogen Pharma, Urotronic, US Biotest, and Vaxiion. He has also been employed by GenesisCare. Neal Shore is an Editorial Board member of Targeted Oncology. Neal Shore was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Independent Institutional Review Boards at all participating institutions approved the study, which was conducted in accordance with International Council for Harmonisation guidelines for Good Clinical Practice and according to the principles of the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent before screening.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Sumitomo Pharma Switzerland, GmbH is the owner of the raw data, which it considers to be proprietary and does not share the data with anyone other than regulatory authorities. At the conclusion of the study, results may be available through ClinicalTrials.gov.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the design and\/or conduct of this study and met the authorship criteria based on the International Committee of Medical Journal Editors. The manuscript was reviewed and approved by all authors. JC, LB, KDC, ED, JO, CD, LG, MG, KM, DM, PS, RT, NS were clinical investigators who also provided medical and scientific expertise regarding study design and data interpretation. YZ was the study statistician. MR and MU served as medical leads from Pfizer and Sumitomo Pharma, respectively.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}